Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult Burkitt lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma
Eligibility Criteria
Inclusion Criteria: Diagnosis of CD20-positive B-cell non-Hodgkin's lymphoma Transplantation candidate Primary induction failure Chemotherapy refractory disease Received at least 3 prior chemotherapy regimens or diagnosis of mantle cell lymphoma Age 19 and over Performance status: WHO 0-2 Life expectancy at least 6 months Absolute neutrophil count at least 1,000/mm3 (unless due to lymphomatous involvement of the marrow) Platelet count more than 50,000/mm3 (unless due to lymphomatous involvement of the marrow) Hemoglobin more than 9.0 g/dL (unless due to lymphomatous involvement of the marrow) Fertile patients must use effective contraception Concurrent non-steroidal hormones for non-lymphoma-related conditions (e.g., insulin for diabetes) allowed Exclusion Criteria: No other concurrent chemotherapy No concurrent corticosteroids except for transient control or prevention of nausea or vomiting No concurrent external beam radiotherapy during transplantation therapy No other concurrent antitumoral or investigational agents No history of T-cell lymphoma No relapse or progression after rituximab therapy within 3 months before transplantation No serious disease or condition that would preclude study Not pregnant or nursing/negative pregnancy test
Sites / Locations
- University of Nebraska Medical Center
Arms of the Study
Arm 1
Experimental
Arm I
Rituxan and BEAM with autologous stem cell transplant